TY - STD TI - Joint United Nations Programme on HIV/AIDS. Global AIDS Update 2016. http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf. Accessed 10 Jan 2018. UR - http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf ID - ref1 ER - TY - JOUR AU - Ajose, O. AU - Mookerjee, S. AU - Mills, E. J. AU - Boulle, A. AU - Ford, N. PY - 2012 DA - 2012// TI - Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis JO - AIDS. VL - 26 UR - https://doi.org/10.1097/QAD.0b013e328351f5b2 DO - 10.1097/QAD.0b013e328351f5b2 ID - Ajose2012 ER - TY - STD TI - World Health Organisation. Global report: UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf. UNAIDS;2013. Accessed 15 Dec 2016. UR - http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf.%20UNAIDS;2013 ID - ref3 ER - TY - JOUR AU - Madec, Y. AU - Leroy, S. AU - Rey-Cuille, M. A. AU - Huber, F. AU - Calmy, A. PY - 2013 DA - 2013// TI - Persistent difficulties in switching to second-line ART in sub-saharan Africa--a systematic review and meta-analysis JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0082724 DO - 10.1371/journal.pone.0082724 ID - Madec2013 ER - TY - STD TI - Somnuek Sungkanuparph WM, 2 Sasisopin Kiertiburanakul,1 Bucha Piyavong,1, Noppanath Chumpathat WC. Options for a Second-Line Antiretroviral Regimen for HIV Type 1–Infected Patients Whose Initial Regimenof a Fixed-Dose Combination of Stavudine,Lamivudine, and Nevirapine Fails. Clin Infect Dis. 2007;44(3):447–52. ID - ref5 ER - TY - STD TI - WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infcetion. .Recommendations for a public health approach. 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1 Accessed 28 May 2017. UR - http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1 ID - ref6 ER - TY - STD TI - WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.Recommendations for a public health approach - Second edition. 2016. http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1. Accessed 22 Dec 2017. UR - http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1 ID - ref7 ER - TY - STD TI - Sigaloff KC, Hamers R, Wallis CL, Kityo C, et al Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58(1):23–31. ID - ref8 ER - TY - JOUR AU - Paton, N. I. AU - Kityo, C. AU - Thompson, J. PY - 2017 DA - 2017// TI - Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial JO - Lancet HIV VL - 4 UR - https://doi.org/10.1016/S2352-3018(17)30065-6 DO - 10.1016/S2352-3018(17)30065-6 ID - Paton2017 ER - TY - STD TI - Hosseinipour MC, van Oosterhout JJG ,Weigel R, Phiri S, et al. the public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23(9):1127–34. ID - ref10 ER - TY - STD TI - Molina JM, Andrade-Villanueva J,Echevarria J, Chetchotisakd P, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Lancet Mar 2008;53(3):323–332. ID - ref11 ER - TY - STD TI - Fernandez-Montero JV, Barreiro P, Soriano V. HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opin Pharmacother Jul 15 2009;10(10):1615–1629. ID - ref12 ER - TY - STD TI - Hirsch MS, Gunthard Hf, Schapiro JM, Brun-Vezinet F, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS society-USA panel. Clin Infec DisJul 15 2008; 47(2): 266–285. ID - ref13 ER - TY - STD TI - WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a Public Health approach.– 2010 revision. 2010. http://apps.who.int/iris/bitstream/10665/44379/1/9789241599764_eng.pdf. Accessed 20 Jul 2017. UR - http://apps.who.int/iris/bitstream/10665/44379/1/9789241599764_eng.pdf ID - ref14 ER - TY - BOOK PY - 2006 DA - 2006// TI - Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. – 2006 revision ID - ref15 ER - TY - STD TI - World Health Organisation. Scaling up Antiretroviral Therapy in Resource -Limited Settings: Treatment Guidelines for A public Health Approach. 2003. https://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf?ua=1. Accessed 20 Jul 2017. UR - https://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf?ua=1 ID - ref16 ER - TY - STD TI - 17th Expert Committee on the Selection and Use of Essential Medicines, Geneva. Application for the listing of Atazanvir for the treatment of HIV-1 infection on the WHO model list of essential medicines Feb 2009. http://www.who.int/selection_medicines/committees/expert/17/application/Atazanavir.pdf. Accessed 1 Nov 2017. UR - http://www.who.int/selection_medicines/committees/expert/17/application/Atazanavir.pdf ID - ref17 ER - TY - STD TI - WHO. What ARV regimen to switch to in adults, pregnant women, Adolescents and children living with HIV (once-daily PI regimens)? 2013. http://apps.who.int/iris/bitstream/10665/90773/1/WHO_HIV_2013.38_eng.pdf. Accessed 15 May 2017. UR - http://apps.who.int/iris/bitstream/10665/90773/1/WHO_HIV_2013.38_eng.pdf ID - ref18 ER - TY - BOOK AU - Jean-Michel Molina, J. A. -. V. AU - Echevarria, J. AU - Chetchotisakd, P. AU - Corral, J. AU - David, N. AU - Moyle, G. AU - Marco Mancini, L. P. AU - Yang, R. AU - Thiry, A. AU - McGrath, D. PY - 2008 DA - 2008// TI - Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovirand emtricitabine, For management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety resultsof the CASTLE study ID - Jean-Michel Molina2008 ER - TY - BOOK PY - 2011 DA - 2011// TI - The integrated National Guidelines on antiretroviral therapy, Prevention of mother to child transmission of HIV and Infant & Young Child Feeding ID - ref20 ER - TY - JOUR AU - Boillat-Blanco, N. AU - Darling, K. E. AU - Schoni-Affolter, F. AU - Vuichard, D. AU - Rougemont, M. AU - Fulchini, R. PY - 2015 DA - 2015// TI - Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV cohort study JO - Antivir Ther VL - 20 UR - https://doi.org/10.3851/IMP2815 DO - 10.3851/IMP2815 ID - Boillat-Blanco2015 ER - TY - JOUR AU - Vandenhende, M. A. AU - Ingle, S. AU - May, M. AU - Chene, G. AU - Zangerle, R. AU - Sighem, A. PY - 2015 DA - 2015// TI - Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients JO - AIDS (London, England) VL - 29 ID - Vandenhende2015 ER - TY - JOUR AU - Chkhartishvili, N. AU - Sharvadze, L. AU - Dvali, N. PY - 2014 DA - 2014// TI - Virologic outcomes of second-line antiretroviral therapy in eastern European country of Georgia JO - AIDS Res Ther VL - 11 UR - https://doi.org/10.1186/1742-6405-11-18 DO - 10.1186/1742-6405-11-18 ID - Chkhartishvili2014 ER - TY - STD TI - Johnson M, Grinsztejn B , Rodriguez C , Coco J, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. Mar 21 2006;20(5):711–718. ID - ref24 ER - TY - STD TI - Ciaffia L, Koulla-Shirob S, Sawadogo A, et al. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. AIDS. Jul 31 2015;29(12): 1473–1481. ID - ref25 ER -